| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/25/2006 | US20060111341 Use of galanthamine and the derivatives thereof in the production of medicaments |
| 05/25/2006 | US20060111340 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 05/25/2006 | US20060111339 Novel oral general anesthetics and metabolitically resistant anticonvulsants |
| 05/25/2006 | US20060111304 For therapy of pancreatitus, bilioecholic, gastroesophical relux (GERD), irritable bowel syndrome (IBS), non ulcerous dyspepsia |
| 05/25/2006 | US20060111290 Stromal-Derived Factor-1 (SDF), G-CSF (granulocyte-colony stimulating factor), stimulating vasculogenesis; improves cardiac function |
| 05/25/2006 | US20060110474 Rubrofusarin glycoside-containing composition |
| 05/25/2006 | US20060110470 Pharmaceutical formulation of traditional chinese medicine for abstinence of drug and preparation method and use thereof |
| 05/25/2006 | US20060110433 Adhesive patch |
| 05/25/2006 | US20060110409 Targeted agents for nerve regeneration |
| 05/25/2006 | US20060110382 For treating a disease medicated by TNF alpha including acute and chronic immune and immunoregulatory disorders and rheumatoid or osteo-arthritis |
| 05/25/2006 | US20060110333 Composition for nasal absorption |
| 05/24/2006 | EP1659131A2 Polypeptides and nucleic acids encoding the same |
| 05/24/2006 | EP1659121A1 1,3-dihydro-2h-indol-2-one derivative |
| 05/24/2006 | EP1659120A1 3-substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists |
| 05/24/2006 | EP1659117A1 2-naphthylimino-1,3-thiazine derivative |
| 05/24/2006 | EP1659114A2 Process for the preparation of bicyclo[3.2.1]octane fused with quinazoline derivatives |
| 05/24/2006 | EP1659112A1 Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor |
| 05/24/2006 | EP1658853A1 Remedy for internal administration against cranial nerve diseases containing mesenchymal cells as the active ingredient |
| 05/24/2006 | EP1658850A1 The use of mirtazapine for the treatment of sleep disorders |
| 05/24/2006 | EP1658292A1 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| 05/24/2006 | EP1658287A1 Pyridinylmorpholine derivatives |
| 05/24/2006 | EP1658277A1 Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament |
| 05/24/2006 | EP1658276A1 Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
| 05/24/2006 | EP1658272A1 Novel gamma-secretase inhibitors |
| 05/24/2006 | EP1658090A2 Agent and method for the treatment and prevention of tse and method for the production of said agent |
| 05/24/2006 | EP1658082A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| 05/24/2006 | EP1658081A2 Immunosuppressive effects of pteridine derivatives |
| 05/24/2006 | EP1658077A2 Dual function compounds and uses thereof |
| 05/24/2006 | EP1658065A2 Using selective antagonists of persistent sodium current to treat neurological disorders and pain |
| 05/24/2006 | EP1658058A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| 05/24/2006 | EP1605932B1 Intranasal formulation of rotigotine |
| 05/24/2006 | EP1553942B1 Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent |
| 05/24/2006 | EP1549639B1 Sulphonamide derivatives as antipsychotic agents |
| 05/24/2006 | EP1506185B1 Compounds and their use as inhibitors of 5-ht |
| 05/24/2006 | EP1485051A4 Method of administering buprenorphine to treat depression |
| 05/24/2006 | EP1478613B1 Substituted 10-aryl-11h-benzo¬b|fluorenes for selective effects on estrogen receptors |
| 05/24/2006 | EP1474425B1 Deazapurines and uses thereof |
| 05/24/2006 | EP1458378B1 Amino acid derivatives useful for the treatment of alzheimer's disease |
| 05/24/2006 | EP1427428B1 Apoptosis-mimicking natural vesicles and use thereof in medical treatment |
| 05/24/2006 | EP1389619B1 Pkb-3564 substance with neovascularization inhibitory activity |
| 05/24/2006 | EP1363912B1 Substituted imidazotriazinones |
| 05/24/2006 | EP1355900B1 Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands |
| 05/24/2006 | EP1341778B1 Klainetin and derivatives thereof, method for their production and the use of the same |
| 05/24/2006 | EP1333841B1 M. tuberculosis chaperonin 10 and uses thereof |
| 05/24/2006 | EP1325002B1 1,2,5,10-tetrahydropyridazino¬4,5-b|quinoline-1,10-diones and their use for the treatment of pain |
| 05/24/2006 | EP1322383B1 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 05/24/2006 | EP1257271B1 Use of pramipexole for the treament of tobacco/nicotine addiction |
| 05/24/2006 | EP1254904B1 Novel piperidine compounds and drugs containing the same |
| 05/24/2006 | EP1212298B1 Isolation of natural l-beta-3-indolylalanine and enrichment of natural aliphatic amino acid mixtures with natural l-beta-3-indolylalanine |
| 05/24/2006 | EP1061887B1 Novel use of phospholipids of vegetable and animal origin in nutritional therapy |
| 05/24/2006 | EP1001974B1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2006 | EP0719295B1 Polymeric matrices and their uses in pharmaceutical compositions |
| 05/24/2006 | DE10248601B4 Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems A pharmaceutical composition for endonasal administration in the treatment of diseases and disorders of the central nervous system |
| 05/24/2006 | DE102004054847A1 Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament Substituted benzoylguanidines, processes for their preparation, their use as a medicament or diagnostic, and they drug-containing |
| 05/24/2006 | CN1777676A Schizophrenia-related voltage-gated ion channel gene and protein |
| 05/24/2006 | CN1777613A New polymorphs of olanzapine hydrochloride |
| 05/24/2006 | CN1777612A New piperidinylamino-thieno[2,3-d] pyrimidine compounds |
| 05/24/2006 | CN1777609A 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists |
| 05/24/2006 | CN1777608A Fused pyrimidine derivative |
| 05/24/2006 | CN1777607A Substituted 8 -pyridinyl-dihydrospiro- cycloalkyl -pyrimido 1,2-a pyrimidin-6-one and 8 -pyrimidin yl-dihydrospiro- cycloalkyl -pyrimido 1,2-a pyrimidin-6-one derivatives |
| 05/24/2006 | CN1777603A Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives |
| 05/24/2006 | CN1777602A Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| 05/24/2006 | CN1777595A Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics |
| 05/24/2006 | CN1777593A Acylaminothiazole derivatives, their preparation and their use as beta starchy peptide to produce inhibitor |
| 05/24/2006 | CN1777585A 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |
| 05/24/2006 | CN1777584A (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht 1f agonists |
| 05/24/2006 | CN1777582A Substituted indoline and indole derivatives |
| 05/24/2006 | CN1777426A Implantable polymeric device for sustained release of dopamine agonist |
| 05/24/2006 | CN1777422A Intranasal formulation of rotigotine |
| 05/24/2006 | CN1777421A Composition for oral administration containing alkylene dioxybenzene derivative |
| 05/24/2006 | CN1775767A New benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them |
| 05/24/2006 | CN1775285A Use of glucoprotein for pharmaceuticals |
| 05/24/2006 | CN1775268A Kidney-tonifying preparation and preparing method |
| 05/24/2006 | CN1775260A Six-medicine preparation and new preparing method |
| 05/24/2006 | CN1775239A Huanwu detoction for supplementing Yang, its preparing process and use |
| 05/24/2006 | CN1257286C Targeted adenovirus vectors for delivery of heterologous genes |
| 05/24/2006 | CN1257169C Bicyclic imidazo-3-yl-amine derivatives |
| 05/24/2006 | CN1257160C Aimoquinoline and aminopyridine derivatives and their use as adenosine A3 ligands |
| 05/24/2006 | CN1256967C Health-preserving liver-protecting drug and method for making same |
| 05/23/2006 | US7049445 for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; beta 3-agonist |
| 05/23/2006 | US7049444 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| 05/23/2006 | US7049443 Such as 2-(3-(Acetyl(((5S)-3-(4-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-3 -fluorophenyl)-2-oxo-1,3-oxazolidin-5-yl)meth yl)amino)-1,1-dimethyl-3-oxopropyl)-3,5-dimethylphenyl dihydrogen phosphate; improved bioavailability |
| 05/23/2006 | US7049439 Immunomodulators for inducing cytokine biosynthesis; viricides; antitumor agents |
| 05/23/2006 | US7049422 Tumor necrosis related receptor, TR7 |
| 05/23/2006 | US7049403 Insulin/IGF/relaxin family polypeptides and DNAS thereof |
| 05/23/2006 | US7049402 Tumor necrosis factor receptor-5 |
| 05/23/2006 | US7049343 Nitrogen compounds such as 3-(N'-(2,6-dinitro-4-trifluoro methylphenyl)-N-(3-methoxyphenylhydrazino)propionic acid, used as glycine transport antagonists for prophylaxis of psychological disorders |
| 05/23/2006 | US7049337 Treating schizophrenia, Parkinson's disease, and cocaine addiction; Central Nervous System (CNS); ring systems substituted with an alkynylamino group; for example, 2-(N-propyn-3-yl-N-(2-cyanoethyl)amino)naphth-7-ol |
| 05/23/2006 | US7049335 3-azabicyclo[3.1.0]hexane derivatives |
| 05/23/2006 | US7049334 Enhancement of learning and memory and treatment of amnesia |
| 05/23/2006 | US7049331 1,2,4-thiadiazole derivatives as melanocortin receptor modulators |
| 05/23/2006 | US7049329 Phenylalkylene-substituted or allyloxyphenylmethyl-substituted, e.g., N-(p-allyloxybenzyl-N-(2-methoxyethyl)-N-(3-phenylallyl)amine; endocannabinoid agonists |
| 05/23/2006 | US7049327 For therapy of pain |
| 05/23/2006 | US7049326 Altering a drug's distribution, metabolism and elimination properties, especially by modifying with aralkyl ester moieties to increase rate of metabolism to inactive and nontoxic metabolites when exposure is halted; surgery, riots |
| 05/23/2006 | US7049325 Quinoline derivatives as anti-inflammatory agents |
| 05/23/2006 | US7049322 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor |
| 05/23/2006 | US7049321 Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor |
| 05/23/2006 | US7049320 Drugs for treating physiological disorder, respiratory disorders, inflammatory disease, skin disorder, and antidepressants, treating bipolar disorder, drug abuse, drug dependence, gastrointestinal disorder, atherosclerosis |
| 05/23/2006 | US7049312 2H-1,4-benzothiazin-3(4H)-one derivative as anticarcinogenic and antiproliferative agent; inhibitors of serine/threonine and tyrosine kinase activity |
| 05/23/2006 | US7049306 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4. |